Vaccination against COVID-19 increased immunity in the population, which reduced viral
transmission and protected against severe disease. However, continuous emergence of …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

The SARS-CoV-2 pandemic has, as of July 2022, infected more than 550 million people and
caused over 6 million deaths across the world. COVID-19 vaccines were quickly developed …

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …

Dear Editor, Since the declaration of public Health Emergency of International Concern
(PHEIC) by the WHO, the COVID-19 pandemic, caused by the severe acute respiratory …

SARS-CoV-2 variants, particularly the recently emerged delta (B. 1.617. 2) variant, have
caused another wave of infection worldwide. 1, 2 Whether these variants are sensitive to the …

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …

The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has
raised concern about potential immune escape. Here, we studied humoral and cellular …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and
recently emerging variants with substitutions in the Spike protein have led to growing …

Multiple SARS-CoV-2 variants have mutations in the spike receptor binding domain (RBD)
with potential to evade neutralizing antibody. In particular, the Beta and Omicron variants …